The CGRP Receptor Antagonist MK0974 Induces EVI1 AML Cell Apoptosis by Disrupting ERK Signaling.

Background/aim: Acute myeloid leukemia (AML) with high expression of the oncogenic transcription factor ecotropic viral integration site-1 (EVI1) (EVI1 AML) is refractory, and there is an urgent need to develop treatment for EVI1 AML. We previously showed that calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein 1 (RAMP1) is highly expressed in EVI1 AML and participates in calcitonin gene-related peptide (CGRP)-induced stress hematopoiesis. This study examined whether MK0974 (a CGRP antagonist) acts as a therapeutic agent in CRLR/RAMP1 AML cell lines.

Materials And Methods: An in vitro experimental system was used to determine the effect of MK0974 on EVI1 AML cell lines. The expression of CRLR and RAMP1-3 in EVI1 and EVI1 AML lines was evaluated by reverse-transcription polymerase chain reaction (RT-PCR). Next, MK0974 was added to the AML cell lines, and cell proliferation, cell cycle and apoptosis assays were carried out using flow cytometry (FCM). Proteins were evaluated using western blot analysis. We also generated AML cell lines with CRLR knockdown and evaluated whether the effect of MK0974 was reduced.

Results: Apoptosis was induced by adding MK0974 to the EVI1 AML cell line. In the EVI1 AML cell line, the addition of MK0974 attenuated the phosphorylation of ERK and p38. These effects were also attenuated by CRLR knockdown.

Conclusion: MK0974, a CGRP receptor antagonist, inhibits the CRLR/RAMP1 complex and induces apoptosis, making it a potential therapeutic agent for CRLR/RAMP1 AML.